Wang Yating, Shi Yu, Xiao Tangli, Bi Xianjin, Huo Qingyu, Wang Shaobo, Xiong Jiachuan, Zhao Jinghong
Department of Nephrology, The Key Laboratory for the Prevention and Treatment of Chronic Kidney Disease of Chongqing, Kidney Center of PLA, Xinqiao Hospital, Army Medical University (Third Military Medical University), Chongqing, PR China.
Kidney Dis (Basel). 2024 Mar 25;10(3):200-212. doi: 10.1159/000538510. eCollection 2024 Jun.
This study aimed to develop and validate machine learning (ML) models based on serum Klotho for predicting end-stage kidney disease (ESKD) and cardiovascular disease (CVD) in patients with chronic kidney disease (CKD).
Five different ML models were trained to predict the risk of ESKD and CVD at three different time points (3, 5, and 8 years) using a cohort of 400 non-dialysis CKD patients. The dataset was divided into a training set (70%) and an internal validation set (30%). These models were informed by data comprising 47 clinical features, including serum Klotho. The best-performing model was selected and used to identify risk factors for each outcome. Model performance was assessed using various metrics.
The findings showed that the least absolute shrinkage and selection operator regression model had the highest accuracy (C-index = 0.71) in predicting ESKD. The features mainly included in this model were estimated glomerular filtration rate, 24-h urinary microalbumin, serum albumin, phosphate, parathyroid hormone, and serum Klotho, which achieved the highest area under the curve (AUC) of 0.930 (95% CI: 0.897-0.962). In addition, for the CVD risk prediction, the random survival forest model with the highest accuracy (C-index = 0.66) was selected and achieved the highest AUC of 0.782 (95% CI: 0.633-0.930). The features mainly included in this model were age, history of primary hypertension, calcium, tumor necrosis factor-alpha, and serum Klotho.
We successfully developed and validated Klotho-based ML risk prediction models for CVD and ESKD in CKD patients with good performance, indicating their high clinical utility.
本研究旨在开发并验证基于血清 Klotho 的机器学习(ML)模型,用于预测慢性肾脏病(CKD)患者的终末期肾病(ESKD)和心血管疾病(CVD)。
使用 400 例非透析 CKD 患者队列,训练了五种不同的 ML 模型,以预测三个不同时间点(3 年、5 年和 8 年)的 ESKD 和 CVD 风险。数据集被分为训练集(70%)和内部验证集(30%)。这些模型由包含 47 个临床特征的数据提供信息,包括血清 Klotho。选择性能最佳的模型并用于识别每个结局的危险因素。使用各种指标评估模型性能。
研究结果表明,最小绝对收缩和选择算子回归模型在预测 ESKD 方面具有最高的准确性(C 指数 = 0.71)。该模型主要包含的特征有估计肾小球滤过率、24 小时尿微量白蛋白、血清白蛋白、磷酸盐、甲状旁腺激素和血清 Klotho,其曲线下面积(AUC)最高,为 0.930(95%CI:0.897 - 0.962)。此外,对于 CVD 风险预测,选择了准确性最高的随机生存森林模型(C 指数 = 0.66),其 AUC 最高为 0.782(95%CI:0.633 - 0.930)。该模型主要包含的特征有年龄、原发性高血压病史、钙、肿瘤坏死因子-α 和血清 Klotho。
我们成功开发并验证了基于 Klotho 的 ML 风险预测模型,用于 CKD 患者的 CVD 和 ESKD 预测,性能良好,表明其具有较高的临床实用性。